Search for: "SANOFI-SYNTHELABO INC" Results 21 - 40 of 45
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
18 Feb 2011, 11:47 am by Sheppard Mullin
The defendants in both sets of actions were Sanofi Aventis and Sanofi-Synthelabo, Inc., Bristol-Myers Squibb Company and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership (collectively “Sanofi”) and Apotex Corporation (“Apotex”). [read post]
25 Jan 2009, 2:36 pm
The last big pharmaceutical industry acquisition came in August 2004, when Paris-based Sanofi-Synthelabo acquired Aventis SA of Strasburg, France, for $64.4 billion to create Sanofi Aventis SA, France's largest drugmaker. [read post]
3 Feb 2010, 2:00 am
Barr Laboratories, Inc. and Mylan Pharma (Patent Docs) (Patently-O) Omnicef (Cefdinir) – US: CAFC on whether a product-by-process claim is infringed by an identical product made by different process: Abbott Labs v Sandoz (IP Frontline) Pertussis vaccines – UK: EWHC dismisses Medeva appeal against pertussis vaccines SPCs refusal (The SPC Blog) Plavix (Clopidogrel) – Canada: Adding some obvious flexibility: Apotex Inc v Sanofi-Synthelabo Canada… [read post]
25 Jun 2007, 2:10 am
DISTRICT COURTSOUTHERN DISTRICT OF NEW YORKIntellectual Property Sale of Generic Version of Plavix Blocked; Infringed Patent Not Proved Invalid or Unenforceable Sanofi-Synthelabo v. [read post]
Services Inc., and Sanofi-Synthelabo, Inc., engaged in unfair and deceptive marketing practices relating to the efficacy of Plavix, an anti-clotting prescription drug. [read post]
28 Nov 2008, 12:49 pm
victories in fight for European BRCA patents (Holman's Biotech IP Blog) Europe: European Commission proposes strategy for dealing with rare diseases (Pharmacapsules @ Gowlings) US: Former House Ways and Means Economist claims 7-year data exclusive period is sufficient (Patent Docs) US: Medco predicts follow-on biologics regulatory pathway by 2011 (Patent Docs) US: Even after patent has expired, District Court has jurisdiction to set exclusivity date: In re Omeprazole Patent Litigation… [read post]
7 Nov 2008, 3:42 am
Sandoz, Inc (Patent Docs) (PATracer) Boniva (Ibandronic acid) – US: Hoffman La Roche files third patent infringement lawsuit against Orchid over generic Boniva (GenericsWeb) Carbatrol (Carbamazepine) – US: Federal Judge grants summary judgment of noninfringement to Corepharma in Carbatrol patent dispute with Shire Laboratories (Law360) Effexor (Venlafaxine) – US: Wyeth settles with fourth drug company, Anchen Pharmaceuticals, over generic Effexor (Law360)… [read post]
13 Oct 2011, 7:45 pm
" Ecolab, 569 F.3d at 1352 (quoting Sanofi-Synthelabo v. [read post]
24 Aug 2011, 9:00 pm
Sanofi-Synthelabo v. [read post]
18 Feb 2020, 4:00 am by Martin Kratz
Pfizer Canada ULC, 2020 FC 1, at para. 42. [3] See Sections 27(3)(b) and 28.3 of the Patent Act, RSC 1985, c P-4 [4] Burton Parsons Chemicals, Inc v Hewlett-Packard (Canada) Ltd, [1976] 1 SCR 555 at 563 [5] Apotex Inc v Sanofi-Synthelabo Canada Inc, 2008 SCC 61 at paragraph 37, [2008] 3 SCR 265; see also Bell Helicopter Textron Canada Limitée v Eurocopter, société par actions simplifiée, 2013 FCA 219 at paragraph 65; Mylan… [read post]
13 May 2009, 11:44 pm
Cir. 2008); see also Sanofi-Synthelabo v. [read post]
30 Nov 2009, 12:00 am
Budejovicky Budvar Narodni Podnik v Anheuser-Busch Inc (Class 46) (IPKat) EPO: Should green technology be subject to compulsory licensing? [read post]
4 Nov 2010, 6:14 am by Lawrence B. Ebert
And although a reference must be enabling to be anticipatory, see Sanofi-Synthelabo, 550 F.3d at 1082, unlike enablement under § 112, a reference need not, as AstraZeneca suggests, demonstrate utility or efficacy to be enabling in the context of § 102, see In re Gleave, 560 F.3d 1331, 1335-36 (Fed. [read post]